Key Developments: SQI Diagnostics Inc (SQD.V)

SQD.V on TSX Venture Exchange

0.37CAD
22 Aug 2014
Price Change (% chg)

$0.05 (+15.63%)
Prev Close
$0.32
Open
$0.33
Day's High
$0.37
Day's Low
$0.33
Volume
13,200
Avg. Vol
11,954
52-wk High
$0.90
52-wk Low
$0.28

Search Stocks

Latest Key Developments (Source: Significant Developments)

SQI Diagnostics contracted to Automate Pathogen Detection Assays
Friday, 22 Aug 2014 08:30am EDT 

SQI Diagnostics Inc:Enters into Master Service Agreement to contract with UK-based company to automate their DNA-based pathogen detection assays.During initial phase of this agreement, SQI will be paid to deliver an automated working prototype of one of customer's assays, operational on SQI's sqid lite(tm) system.Initial phase is scheduled for completion by mid-Sept 2014.It is anticipated that other molecular diagnostic tests will be commissioned in separate agreement following successful implementation of initial phase.First assay being automated is used to identify pathogens in raw milk from dairy cows.Currently, dairy cows are routinely tested for health through global network of laboratories and when symptoms of bacterial infections appear, pathogens are commonly detected using traditional plate cultures.New application can be used for much faster and more accurate identification of multiple pathogens simultaneously.The UK-based company is developing additional assays for agriculture, food safety and human pathogen testing, intended to screen high volumes of samples on a regular basis.  Full Article

SQI Diagnostics Inc hired by global pharmaceutical company to develop two prototype multiplex immunoassays for evaluation
Tuesday, 20 May 2014 09:05am EDT 

SQI Diagnostics Inc:Says it is being paid by one of the pharmaceutical companies to develop and validate two custom multiplex anti-drug-antibody (ADA) assays.This new customer will evaluate these two products using an established drug from its portfolio in order to assess the capabilities and performance of SQI's technologies.  Full Article

SQI Diagnostics Inc completes C$4.2 mln equity financing
Thursday, 10 Apr 2014 10:35am EDT 

SQI Diagnostics Inc:Closes public offering of 8,400,000 units at price of C$0.50 per Unit for gross proceeds of C$4.2 mln.Each Unit is comprised of one common share and one Common Share purchase warrant.Each Warrant is exercisable at price of C$0.65 and entitles the holder thereof to acquire one common share until April 10, 2016.Intends to use net proceeds to fund product development and commercialization programs, sales and marketing and for general working capital purposes.  Full Article

SQI Diagnostics Inc files final prospectus for equity financing
Friday, 4 Apr 2014 11:09am EDT 

SQI Diagnostics Inc:Issue minimum of 8,000,000 units at a price of C$0.50 per unit.Gross proceeds will be C$4.0 mln.Use of net proceeds to fund product development and commercialization programs, sales and marketing and for general working capital purposes.Closing is expected on or about April 10.  Full Article

SQI Diagnostics Inc signs commercial agreement with Global Pharma Customer
Thursday, 20 Mar 2014 03:27pm EDT 

SQI Diagnostics Inc:Expands product development relationship with a global pharmaceutical company.To develop a custom multiplex test to support the pharmaceutical company's clinical drug development activities, through the entering into of a revenue-generating agreement with Global Pharma 1 to develop a 21-plex protein microarray.  Full Article

SQI Diagnostics Inc announces closing of private placement
Monday, 27 Jan 2014 04:28pm EST 

SQI Diagnostics Inc:Says it raised gross proceeds of C$1.483 mln through a non-brokered private placement of 2,965,000 units priced at $0.50 per unit.Says each Unit consists of one common share and one common share purchase warrant.Says each common share purchase warrant will entitle the holder to purchase one common share at a price of $0.65 for a period of two years from the date of issuance.Says it intends to use the net proceeds to fund the company's product development and commercialization programs and partner development, sales and marketing and for general working capital purposes.  Full Article

SQI Diagnostics Inc secures commercial agreement with Global Pharma
Wednesday, 18 Dec 2013 04:15pm EST 

SQI Diagnostics Inc:Says it has entered into a commercial product development and services agreement with an Irvine California-based global pharmaceutical company.Says under the terms of the agreement SQI will be paid to build a customized, 6-plex anti-drug antibody (ADA) assay to detect and measure immunogenic responses to a drug in the customer's drug pipeline.Says the agreement also compensates SQI to provide preliminary data using this custom assay on a set of the customer's pre-clinical samples provided to SQI.Says the agreement includes payment for the services for this phase of the project as well as for the consumables used during development and sample testing.  Full Article

SQI Diagnostics Inc Announces Changes To Its Board Of Directors
Tuesday, 1 Oct 2013 09:32am EDT 

SQI Diagnostics Inc announced the appointment of Andrew Morris, President and CEO of SQI Diagnostics to the Board of Directors. Andrew Morris has been with SQI for over nine years and acted as the Company`s Chief Financial Officer prior to being promoted to President and CEO in June, 2013. Mr. Morris replaces Dr. Peter Lea who has resigned from the Board, effective immediately.  Full Article

SQI Diagnostics Inc Announces New Chairman
Monday, 3 Jun 2013 08:00am EDT 

SQI Diagnostics Inc announced the promotion of Claude Ricks to Chairman of the Board of Directors, replacing Eric Schneider as Chairman. Mr. Schneider will continue to serve as a Director on the Board and will continue to serve on the Audit and Special Committees and as Chair of the Compensation Committee.  Full Article

SQI Diagnostics Inc Announces Closing Of Private Placement
Friday, 3 May 2013 08:30am EDT 

SQI Diagnostics Inc announced it raised gross proceeds of CAD3.845 million through a non-brokered private placement (the Private Placement) of 5,126,044 units (Units) priced at $0.75 per unit. Each Unit consists of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at a price of $1.10 for a period of two years from the date of issuance. After giving effect to the issuance of the shares and exercise of warrants of the Private Placement the Company will have 50,078,352 shares outstanding. The Private Placement is subject to all necessary regulatory and stock exchange approvals. The securities being issued pursuant to the Private Placement will be subject to a four month hold period in accordance with applicable Canadian securities law. SQI intends to use the net proceeds to fund the Company's product development and commercialization programs, sales and marketing and for general working capital purposes.  Full Article

Search Stocks